Dorzolamide/timolol
Alternative Names: Cosopt; Cosopt Mini; Cosopt PF; L-671152/timolol; MK-507/timololLatest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co; Merck Sharp & Dohme
- Developer Akorn; Merck & Co; Merck Sharp & Dohme; Purdue Pharma; Santen Pharmaceutical; Sidus
- Class Antiglaucomas; Propanolamines; Sulfonamides; Thiadiazoles; Thiophenes
- Mechanism of Action Beta adrenergic receptor antagonists; Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 09 Dec 2015 COSOPT® licensed to Purdue Pharma in Canada
- 10 Mar 2015 Japanese Ministry of Health, Labour and Welfare approves a preservative free formulation of dorzolamide/timolol for treatment of Glaucoma and Ocular hypertension in Japan
- 15 Aug 2014 Santen Pharmaceutical files for approval of a preservative-free formulation of Dorzolamide/timolol in Japan